Posted by Michael Wonder on 07 Jun 2017
FDA approves two month Aristada for treatment of schizophrenia
6 June 2017 - Approval expands Aristada's product offerings to Include once monthly, once every six weeks and once every two-months dosing durations.
Alkermes today announced that the U.S. FDA has approved two month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
Aristada is now FDA approved in four doses and three dosing duration options (441 mg, 662 mg or 882 mg once monthly, 882 mg once every six weeks and 1064 mg once every two months) and can be initiated at any dose or interval, offering an unprecedented range of flexibility to patients and healthcare providers. The new two month dose is expected to be available in mid June.
